Healius Ltd (ASX: HLS) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Healius Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Healius Ltd (ASX: HLS)
Latest News

Share Market News
Here's how the ASX 200 market sectors stacked up this week

Share Market News
Here are the top 10 ASX 200 shares today

Share Market News
Here are the top 10 ASX 200 shares today

Share Market News
Here's why you might have just bought Healius shares

Share Market News
Here are the top 10 ASX 200 shares today

Share Gainers
Why Collins Foods, Healius, Imugene, and Link shares are climbing today

Healthcare Shares
Healius share price rallies amid corporate reset

Share Gainers
Here are the top 10 ASX 200 shares today

Share Gainers
Why Adore Beauty, Catapult, Healius, and Ramelius shares are storming higher

Share Gainers
Why Boss Energy, Delta Lithium, Healius, and Origin shares are rising

Share Fallers
Why Brainchip, Healius, Latin Resources, and Praemium shares are sinking today

Healthcare Shares
Why are Healius shares crashing 35% on Wednesday?
Frequently Asked Questions
-
Yes, Healius has historically paid two fully franked shareholder dividends a year.
-
Healius has generally paid its shareholder dividends in March/April and September/October.
-
Healius Ltd listed on the ASX on 3 July 1998.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
07 Sep 2022 | $0.0600 | 100.00% | Final | 21 Sep 2022 |
24 Mar 2022 | $0.1000 | 100.00% | Interim | 05 Apr 2022 |
13 Sep 2021 | $0.0675 | 100.00% | Final | 08 Oct 2021 |
25 Mar 2021 | $0.0650 | 100.00% | Interim | 15 Apr 2021 |
26 Mar 2020 | $0.0260 | 100.00% | Interim | 15 Oct 2020 |
29 Aug 2019 | $0.0340 | 100.00% | Final | 27 Sep 2019 |
15 Mar 2019 | $0.0380 | 100.00% | Interim | 26 Mar 2019 |
27 Aug 2018 | $0.0550 | 100.00% | Final | 17 Sep 2018 |
16 Mar 2018 | $0.0510 | 100.00% | Interim | 27 Mar 2018 |
31 Aug 2017 | $0.0000 | 100.00% | Final | 18 Sep 2017 |
17 Mar 2017 | $0.0480 | 100.00% | Interim | 28 Mar 2017 |
01 Sep 2016 | $0.0640 | 100.00% | Final | 19 Sep 2016 |
18 Mar 2016 | $0.0560 | 50.00% | Interim | 29 Mar 2016 |
26 Aug 2015 | $0.1100 | 50.00% | Final | 14 Sep 2015 |
18 Mar 2015 | $0.0900 | 100.00% | Interim | 07 Apr 2015 |
27 Aug 2014 | $0.1100 | 100.00% | Final | 15 Sep 2014 |
17 Mar 2014 | $0.0900 | 100.00% | Interim | 07 Apr 2014 |
16 Sep 2013 | $0.1100 | 100.00% | Final | 08 Oct 2013 |
18 Mar 2013 | $0.0650 | 100.00% | Interim | 08 Apr 2013 |
17 Sep 2012 | $0.0600 | 100.00% | Final | 08 Oct 2012 |
26 Mar 2012 | $0.0500 | 100.00% | Interim | 16 Apr 2012 |
19 Sep 2011 | $0.0500 | 100.00% | Final | 10 Oct 2011 |
21 Mar 2011 | $0.0300 | 100.00% | Interim | 11 Apr 2011 |
20 Sep 2010 | $0.1000 | 100.00% | Final | 11 Oct 2010 |
05 Mar 2010 | $0.1500 | 100.00% | Interim | 29 Mar 2010 |
07 Sep 2009 | $0.0700 | 100.00% | Final | 28 Sep 2009 |
16 Feb 2009 | $0.0700 | 100.00% | Interim | 09 Mar 2009 |
08 Sep 2008 | $0.0500 | 100.00% | Final | 09 Oct 2008 |
22 Feb 2008 | $0.2200 | 100.00% | Interim | 17 Mar 2008 |
31 Aug 2007 | $0.2400 | 100.00% | Final | 24 Sep 2007 |
09 Mar 2007 | $0.2100 | 100.00% | Interim | 02 Apr 2007 |
09 Oct 2006 | $0.0800 | 100.00% | Special Cash | 30 Oct 2006 |
04 Sep 2006 | $0.2200 | 100.00% | Final | 25 Sep 2006 |
20 Feb 2006 | $0.2000 | 100.00% | Interim | 13 Mar 2006 |
22 Aug 2005 | $0.1300 | 100.00% | Final | 12 Sep 2005 |
08 Apr 2004 | $0.0750 | 100.00% | Interim | 03 May 2004 |
HLS ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Healius Ltd
Healius Ltd (ASX: HLS) operates a network of pathology laboratories, diagnostic imaging centres, and day hospitals across Australia.
The company is Australia's second-largest pathology provider with around 2,000 collection sites and almost 100 pathology laboratories operating under a portfolio of brand names. The company says one in three pathology samples taken in Australia is tested in a Healius laboratory. It also operates around 150 imaging centres in public and private hospitals, medical centres, and community centres.
The company has identified its short-stay and day hospitals as a growth segment. It currently operates 15 day hospitals as well as four major IVF clinics.
HLS Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
01 Dec 2023 | $1.59 | $0.09 | 6.00% | 3,273,815 | $1.50 | $1.59 | $1.45 |
30 Nov 2023 | $1.50 | $0.00 | 0.00% | 3,631,212 | $1.53 | $1.55 | $1.41 |
29 Nov 2023 | $1.50 | $0.09 | 6.36% | 4,947,630 | $1.45 | $1.57 | $1.45 |
28 Nov 2023 | $1.42 | $0.09 | 6.77% | 3,881,344 | $1.39 | $1.44 | $1.38 |
27 Nov 2023 | $1.33 | $0.03 | 2.31% | 2,709,322 | $1.34 | $1.41 | $1.33 |
24 Nov 2023 | $1.30 | $0.01 | 0.78% | 7,215,809 | $1.31 | $1.34 | $1.29 |
23 Nov 2023 | $1.29 | $0.07 | 5.71% | 7,633,360 | $1.23 | $1.35 | $1.22 |
22 Nov 2023 | $1.23 | $-0.47 | -27.67% | 17,234,768 | $1.28 | $1.28 | $1.18 |
17 Nov 2023 | $1.70 | $-0.06 | -3.41% | 745,813 | $1.75 | $1.80 | $1.70 |
16 Nov 2023 | $1.76 | $0.00 | 0.00% | 1,397,211 | $1.77 | $1.78 | $1.74 |
15 Nov 2023 | $1.76 | $0.03 | 1.74% | 586,898 | $1.73 | $1.76 | $1.71 |
14 Nov 2023 | $1.73 | $0.09 | 5.51% | 949,982 | $1.67 | $1.73 | $1.66 |
13 Nov 2023 | $1.63 | $0.00 | 0.00% | 2,967,566 | $1.63 | $1.65 | $1.59 |
10 Nov 2023 | $1.64 | $-0.07 | -4.09% | 1,399,491 | $1.69 | $1.70 | $1.61 |
09 Nov 2023 | $1.71 | $-0.12 | -6.55% | 2,372,617 | $1.82 | $1.82 | $1.70 |
08 Nov 2023 | $1.83 | $0.03 | 1.66% | 912,596 | $1.80 | $1.88 | $1.79 |
07 Nov 2023 | $1.80 | $0.09 | 5.26% | 1,843,070 | $1.71 | $1.83 | $1.71 |
06 Nov 2023 | $1.71 | $-0.04 | -2.28% | 1,255,522 | $1.76 | $1.78 | $1.68 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
11 Sep 2023 | Jennifer (Jenny) Macdonald | Buy | 8,000 | $20,229 |
On-market trade.
|
04 Sep 2023 | Sally Evans | Exercise | 6,038 | $20,000 |
Conversion of securities. cash equivalent using the volume weighted average price
|
04 Sep 2023 | Sally Evans | Buy | 6,038 | $20,000 |
Conversion of securities. cash equivalent using the volume weighted average price
|
04 Sep 2023 | John Mattick | Exercise | 7,547 | $25,000 |
Conversion of securities. cash equivalent using the volume weighted average
price |
04 Sep 2023 | John Mattick | Buy | 7,547 | $25,000 |
Conversion of securities. cash equivalent using the volume weighted average
price |
04 Sep 2023 | Gordon Davis | Buy | 12,075 | $40,000 |
Conversion of securities. cash equivalent using the volume weighted
average price |
04 Sep 2023 | Gordon Davis | Exercise | 12,075 | $40,000 |
Conversion of securities. cash equivalent using the volume weighted
average price |
01 Sep 2023 | Kathryn (Kate) McKenzie | Buy | 20,000 | $55,200 |
On-market trade.
|
31 Aug 2023 | Maxine Jaquet | Issued | 41,066 | $114,984 |
Conversion of securities.
|
31 Aug 2023 | Maxine Jaquet | Exercise | 41,066 | $114,984 |
Conversion of securities. 371,859 Performance Rights
|
31 Aug 2023 | Jennifer (Jenny) Macdonald | Buy | 22,500 | $61,200 |
On-market trade.
|
30 May 2023 | Maxine Jaquet | Issued | 371,859 | $1,160,200 |
Issue of securities. 4,12,925 Performance Rights
|
10 Mar 2023 | Sally Evans | Buy | 6,037 | $20,000 |
Conversion of securities. VWAP
|
10 Mar 2023 | Sally Evans | Exercise | 6,037 | $20,000 |
Conversion of securities. VWAP, 6,038 NED Share Rights
|
10 Mar 2023 | John Mattick | Buy | 7,546 | $25,000 |
Conversion of securities. VWAP
|
10 Mar 2023 | John Mattick | Exercise | 7,546 | $25,000 |
Conversion of securities. VWAP, 7,547 NED Share Rights
|
10 Mar 2023 | Gordon Davis | Exercise | 12,075 | $40,000 |
Conversion of securities. VWAP, 12,075 NED Share Rights
|
10 Mar 2023 | Gordon Davis | Buy | 12,075 | $40,000 |
Conversion of securities. VWAP
|
28 Feb 2023 | Jennifer (Jenny) Macdonald | Buy | 37,500 | $103,162 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Dr Michael Philip Stanford | Non-Executive Director | Sep 2023 |
Dr Stanford AM is a Non-Executive Director across a range of industries including healthcare, aged care and education. His experience includes ASX-listed businesses, private equity backed companies and not for profit organisations, and includes dealing with Federal and State Governments Commencing his career as a Doctor, Michael progressed into hospital administration and brings over 20 years experience as a Chief Executive Officer and Managing Director of large multi-campus and multi service health care organisations with national and international areas of operation, including St John of God Health Care, Australian Hospital Care Ltd, North-Western Health. North-Eastern Health Care Network and Austin & Repatriation Medical Centre. Dr Stanford is a former Non-Executive Director of Healthscope, Virtus Health and Australian Clinical Labs. He is currently the Chair of Diabetes Australia and genU, a disability support service provider. He is also a board member for the Royal Australian College of General Practitioners.
|
Professor John Mattick | Non-Executive Director | Mar 2022 |
Professor Mattick is a Professor in the School of Biotechnology and Biomolecular Science at UNSW Sydney. From 2018 to 2010, he was Chief Executive of Genomics England, which was established by the UK government to foster the use of genetic information in healthcare. He was Director of the Garvan Institute of Medical Research in Sydney from 2012 to 2018, where he established throughput NATA accredited DNA sequencing and genome analysis facilities. John was a member of the Australian Health Ethics Committee of the National Health & Medical Research Council from 1997 to 2003, an advisor to the Australian Law Reform Commission's Inquiry into the Protection of Human Genetic Information and Gene Patenting & Human Health, and the AHEC Committee to Revise the Ethical Guidelines on Assisted Reproductive Technology. He is a member of the Risk Management Committee.
|
Mr Gordon Richard Davis | Non-Executive Director | Aug 2015 |
Mr Davis has been an executive or non-executive director of ASX listed companies for 17 years. Before becoming a Non-Executive Director, he was Managing Director of AWB Limited between 2006 and 2010 and had a career, managing operating businesses in chemicals and agriculture. Gordon joined the Healius Board at a time of some corporate uncertainty, and has experience in governance and business transformation. He served as Policy Advisor to the federal Leader of the Opposition from 1990 to 1993 in the fields of environment, science and resources.
|
Ms Kathryn (Kate) Mary McKenzie | Non-Executive Director | Feb 2021 |
Ms McKenzie has experience in change management and digital transformation. She started her career in the public sector, where among other things, she was involved in aspects of health policy, including a state-based review of health system and re-negotiation of a Medicare agreement, and had involvement in working with Treasury on health budget allocations and methodologies. Kate joined Telstra in 2004 and held a range of executive roles in strategy, marketing, products and operations (responsible for networks, IT, field services and property). She was CEO of Chorus, a publicly listed NZ telco, for three years from 2017.She was appointed Chair of the Risk Management Committee in January 2023 and is a member of the People & Governance Committee.
|
Ms Sally Evans | Non-Executive Director | Aug 2018 |
Ms Evans has over 30 years of experience in private, government and social enterprise sectors and has worked in Australia, New Zealand, the United Kingdom and Hong Kong with responsibilities across the broader Asia Pacific region. With leadership experience, Sally moved to asset management in social infrastructure covering debt and equity raisings, investor relations, acquisitions and governance. She is Chair of the People & Governance Committee and a member of the Risk Management Committee.
|
Ms Maxine Jaquet | Chief Financial OfficerChief Operating OfficerChief Executive OfficerManaging Director | Mar 2023 |
Ms Jaquet has led efforts, generating substantial margin improvement and business growth. She has also established and managed international partnerships, and has commercial and operational line management experience across industrials and consumer sectors. Maxine's record at Healius includes leading the portfolio strategy which created a pure diagnostics business, building a dynamic leadership team, investing in edge technology, establishing and growing the private-billing general practitioner network, Health & Co. prior to its sale and leading two efficiency reviews with significant productivity gains
|
Mr Charlie Taylor | Non-Executive Director | Mar 2023 |
Mr Taylor has over 30 years of experience in advisory having recently retired as Senior Partner at McKinsey where he led the Health and Public Sector practices. He has advised many of Australia's private and public sector healthcare organisations on topics including strategy, digital, operations and growth transformations, global expansion and supply chains, mergers and acquisitions and board governance. Charlie initiated multi-year research efforts on healthcare, COVID response, productivity and innovation and has published articles and reports on healthcare reform lessons from around the globe. Charlie is currently a part-time senior board advisor at McKinsey for the Health and Public Sector practice, a Director of MacLauglin River Pastoral Company, a member of the strategic advisory committee For Purpose Investment Partners and was recently appointed as Chair of the NSW Innovation and Productivity Commission. Charlie is the Honorary Federal Treasurer for the Liberal Party and a Board member on the Federal Executive. is a member of the People & Governance Committees.
|
Mr Ravi Jeyaraj | Non-Executive Director | Nov 2023 |
--
|
Mrs Mary Weaver | Company Secretary | Mar 2023 |
-
|
Mr Stephen Humphries | Company Secretary | Mar 2023 |
-
|
Paul Anderson | Chief Financial Officer |
-
|
|
Mary Weaver | Company Secretary |
-
|
|
Stephen Humphries | Company Secretary |
-
|
|
Jan van Rooyen | Group Executive |
-
|
|
Janet Payne | Group Executive Corporate Affairs |
-
|
|
Mark Neeham | Group Executive Government Affairs |
-
|
|
John McKechnie | Group Executive Pathology |
-
|
|
Jon Eide | Group Executive Commercial and Customer |
-
|
|
Phil Lucas | Group Executive Lumus Imaging |
-
|
|
Arjun Narang | Group Executive Operations Transformation |
-
|
|
Prasad Arav | Group Executive. Digital and Technology |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED(i) | 179,525,030 | 31.51% |
Citicorp Nominees Pty Limited | 113,011,084 | 19.84% |
J P Morgan Nominees Australia Pty Limited | 101,426,357 | 17.80% |
National Nominees Limited | 41,431,994 | 7.27% |
Argo Investments Limited | 19,132,634 | 3.36% |
Bnp Paribas Noms Pty Ltd <Drp> | 13,878,419 | 2.44% |
HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/ | 3,770,723 | 0.66% |
Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 3,577,160 | 0.63% |
Bnp Paribas Nominees Pty Ltd <Agency Lending Drp A/C> | 3,367,888 | 0.59% |
Ubs Nominees Pty Ltd | 3,150,206 | 0.55% |
Rinrim Pty Ltd | 2,362,047 | 0.41% |
BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> | 1,204,931 | 0.21% |
Ecapital Nominees Pty Limited <Accumulation A/C> | 1,032,081 | 0.18% |
Alphagen Capital Pty Ltd | 1,000,000 | 0.18% |
HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED(ii) | 704,441 | 0.12% |
Joromada Pty Ltd | 680,000 | 0.12% |
Netwealth Investments Limited <Wrap Services A/C> | 636,689 | 0.11% |
Mr Gregory Anthony Thomas Bateman | 636,213 | 0.11% |
Nulis Nominees (Australia) Limited <Navigator Mast Plan Sett A/C> | 580,893 | 0.10% |
HSBC Custody Nominees (Australia) Limited Gsco Eca | 569,088 | 0.10% |